JPMorgan Chase & Co. Sells 183,798 Shares of Indivior PLC $INDV

JPMorgan Chase & Co. lowered its stake in shares of Indivior PLC (NASDAQ:INDV) by 47.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,588 shares of the company’s stock after selling 183,798 shares during the quarter. JPMorgan Chase & Co.’s holdings in Indivior were worth $5,005,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in INDV. CWM LLC bought a new stake in shares of Indivior during the 3rd quarter valued at $25,000. Quarry LP bought a new position in shares of Indivior in the third quarter worth $26,000. Raymond James Financial Inc. acquired a new position in Indivior in the second quarter valued at about $26,000. Plato Investment Management Ltd acquired a new position in Indivior in the third quarter valued at about $52,000. Finally, Blue Trust Inc. bought a new stake in Indivior during the third quarter worth about $99,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Indivior

In other news, Director Daniel A. Ninivaggi acquired 775 shares of Indivior stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director directly owned 16,923 shares of the company’s stock, valued at approximately $598,904.97. The trade was a 4.80% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Keith Humphreys bought 775 shares of the company’s stock in a transaction on Monday, January 5th. The stock was purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director directly owned 5,802 shares of the company’s stock, valued at approximately $205,332.78. The trade was a 15.42% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 5,842 shares of company stock valued at $203,342.

Indivior Trading Down 0.6%

INDV opened at $30.47 on Friday. The company has a market cap of $3.71 billion, a P/E ratio of 18.58 and a beta of 0.88. The company’s 50 day moving average is $32.56 and its 200-day moving average is $31.13. Indivior PLC has a 1-year low of $8.64 and a 1-year high of $38.00.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Friday, February 27th. The company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The business had revenue of $358.00 million during the quarter, compared to the consensus estimate of $305.62 million. On average, equities analysts forecast that Indivior PLC will post 1.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on INDV shares. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. HC Wainwright increased their price target on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th. Finally, Northland Securities set a $50.00 target price on Indivior in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $39.33.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.